NZ236000A - Oligomeric monoclonal igg antibody composition - Google Patents

Oligomeric monoclonal igg antibody composition

Info

Publication number
NZ236000A
NZ236000A NZ236000A NZ23600090A NZ236000A NZ 236000 A NZ236000 A NZ 236000A NZ 236000 A NZ236000 A NZ 236000A NZ 23600090 A NZ23600090 A NZ 23600090A NZ 236000 A NZ236000 A NZ 236000A
Authority
NZ
New Zealand
Prior art keywords
igg antibody
antibody composition
monoclonal igg
oligomeric monoclonal
oligomeric
Prior art date
Application number
NZ236000A
Inventor
Walt W Shuford
Linda J Harris
Howard V Raff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NZ236000A publication Critical patent/NZ236000A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
NZ236000A 1989-11-07 1990-11-07 Oligomeric monoclonal igg antibody composition NZ236000A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43270089A 1989-11-07 1989-11-07

Publications (1)

Publication Number Publication Date
NZ236000A true NZ236000A (en) 1993-09-27

Family

ID=23717254

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ236000A NZ236000A (en) 1989-11-07 1990-11-07 Oligomeric monoclonal igg antibody composition

Country Status (8)

Country Link
EP (1) EP0462246A4 (en)
JP (1) JPH04505709A (en)
AU (1) AU648056B2 (en)
CA (1) CA2045150A1 (en)
IE (1) IE904015A1 (en)
NZ (1) NZ236000A (en)
PT (1) PT95809A (en)
WO (1) WO1991006305A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
JPH06500780A (en) * 1990-08-31 1994-01-27 ブリストル―マイアーズ　スクイブ　カンパニー homozygous immunoglobulin
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
EP1817340B1 (en) 2004-11-12 2012-05-16 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
PL2383297T3 (en) 2006-08-14 2013-06-28 Xencor Inc Optimized antibodies that target CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
LT2808343T (en) 2007-12-26 2019-09-10 Xencor Inc. Fc variants with altered binding to FcRn
EP2249661B1 (en) 2008-01-22 2018-05-16 Multimerics APS Products and methods to prevent infection
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
WO2010112193A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010115552A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
AU2010233993A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
JP5616428B2 (en) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
RU2013110875A (en) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг SPECIFIC ANTIBODIES CONTAINING DISSULPHIDE-STABILIZED Fv Fragment
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
KR20140127854A (en) 2012-02-10 2014-11-04 제넨테크, 인크. Single-chain antibodies and other heteromultimers
EA201401077A1 (en) 2012-04-05 2015-02-27 Ф.Хоффманн-Ля Рош Аг BISPECIFIC ANTIBODIES TO HUMAN TWEAK AND HUMAN IL17 AND THEIR APPLICATION
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
JP6148729B2 (en) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Covalently bound antigen-antibody conjugate
WO2014006123A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-biotin antibodies and methods of use
KR20150023938A (en) 2012-07-04 2015-03-05 에프. 호프만-라 로슈 아게 Anti-theophylline antibodies and methods of use
CN104341504B (en) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 Bispecific antibody
WO2015079977A1 (en) * 2013-11-26 2015-06-04 シャープ株式会社 Antibody separation method, antibody evaluation method, medicine evaluation method, and 2-d antibody electrophoresis kit
PL3083680T3 (en) 2013-12-20 2020-06-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
KR102278429B1 (en) 2014-01-03 2021-07-16 에프. 호프만-라 로슈 아게 Covalently linked polypeptide toxin-antibody conjugates
JP6476194B2 (en) 2014-01-03 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific anti-hapten / anti-blood brain barrier receptor antibodies, complexes thereof, and their use as blood brain barrier shuttles
MX2016008189A (en) 2014-01-03 2016-09-29 Hoffmann La Roche Covalently linked helicar-anti-helicar antibody conjugates and uses thereof.
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
ES2764111T3 (en) 2014-12-03 2020-06-02 Hoffmann La Roche Multispecific antibodies
JP6619460B2 (en) 2015-06-24 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Humanized anti-tau (pS422) antibodies and methods of use
CN113495141A (en) * 2020-03-20 2021-10-12 迈克生物股份有限公司 2019 novel coronavirus IgM antibody detection kit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8719963D0 (en) * 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
NZ226694A (en) * 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
WO1991019515A1 (en) * 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity

Also Published As

Publication number Publication date
IE904015A1 (en) 1991-05-08
WO1991006305A1 (en) 1991-05-16
AU648056B2 (en) 1994-04-14
CA2045150A1 (en) 1991-05-08
JPH04505709A (en) 1992-10-08
AU7030391A (en) 1991-05-31
PT95809A (en) 1991-09-13
EP0462246A1 (en) 1991-12-27
EP0462246A4 (en) 1992-11-25

Similar Documents

Publication Publication Date Title
NZ236000A (en) Oligomeric monoclonal igg antibody composition
GB8608068D0 (en) Monoclonal antibodies
EP0580859A4 (en) Anti-eda monoclonal antibody
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
GB8621910D0 (en) Monoclonal antibodies
IL92232A0 (en) Anti-fucosylceramide monoclonal antibody
EP0506523A3 (en) Monoclonal antibodies
GB9204928D0 (en) Monoclonal antibody production
EP0267601A3 (en) Anti-pci monoclonal antibody
EP0511300A4 (en) Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
GB8616174D0 (en) Monoclonal antibodies
ZA89258B (en) Monoclonal antibodies
GB8927389D0 (en) Monoclonal antibodies
GB8820036D0 (en) Monoclonal antibodies
EP0265847A3 (en) Monoclonal antibody
GB8610203D0 (en) Monoclonal antibodies
GB8610202D0 (en) Monoclonal antibodies
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0336441A3 (en) Anti-cpbii monoclonal antibody
IE893593L (en) Anti-fucosylcermiade monoclonal antibody
GB8619905D0 (en) Monoclonal antibody
IE891298L (en) Monoclonal antibodies
IE890064L (en) Monoclonal antibodies
IE892557L (en) Monoclonal antibodies